SI2970221T1 - Inhibitorji cdc7 - Google Patents

Inhibitorji cdc7

Info

Publication number
SI2970221T1
SI2970221T1 SI201430280T SI201430280T SI2970221T1 SI 2970221 T1 SI2970221 T1 SI 2970221T1 SI 201430280 T SI201430280 T SI 201430280T SI 201430280 T SI201430280 T SI 201430280T SI 2970221 T1 SI2970221 T1 SI 2970221T1
Authority
SI
Slovenia
Prior art keywords
cdc7 inhibitors
cdc7
inhibitors
Prior art date
Application number
SI201430280T
Other languages
English (en)
Inventor
Robert Dean Dally
Timothy Andrew Woods
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of SI2970221T1 publication Critical patent/SI2970221T1/sl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
SI201430280T 2013-03-14 2014-03-07 Inhibitorji cdc7 SI2970221T1 (sl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361782798P 2013-03-14 2013-03-14
US201361789108P 2013-03-15 2013-03-15
PCT/US2014/021466 WO2014143601A1 (en) 2013-03-14 2014-03-07 CDC7 Inhibitors
EP14712966.2A EP2970221B1 (en) 2013-03-14 2014-03-07 Cdc7 inhibitors

Publications (1)

Publication Number Publication Date
SI2970221T1 true SI2970221T1 (sl) 2017-08-31

Family

ID=50382704

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201430280T SI2970221T1 (sl) 2013-03-14 2014-03-07 Inhibitorji cdc7

Country Status (37)

Country Link
US (1) US9156824B2 (sl)
EP (1) EP2970221B1 (sl)
JP (1) JP6064079B2 (sl)
KR (1) KR101718645B1 (sl)
CN (1) CN105008351B (sl)
AP (1) AP2015008734A0 (sl)
AU (1) AU2014228374B2 (sl)
BR (1) BR112015020466B1 (sl)
CA (1) CA2900773C (sl)
CL (1) CL2015002530A1 (sl)
CR (1) CR20150416A (sl)
CY (1) CY1119199T1 (sl)
DK (1) DK2970221T3 (sl)
EA (1) EA027012B1 (sl)
ES (1) ES2639793T3 (sl)
GT (1) GT201500263A (sl)
HK (1) HK1212696A1 (sl)
HR (1) HRP20171151T1 (sl)
HU (1) HUE033482T2 (sl)
IL (1) IL240962B (sl)
JO (1) JO3383B1 (sl)
LT (1) LT2970221T (sl)
ME (1) ME02805B (sl)
MX (1) MX363438B (sl)
MY (1) MY188145A (sl)
NZ (1) NZ710392A (sl)
PE (1) PE20151654A1 (sl)
PH (1) PH12015502091A1 (sl)
PL (1) PL2970221T3 (sl)
PT (1) PT2970221T (sl)
RS (1) RS56122B1 (sl)
SG (1) SG11201507541PA (sl)
SI (1) SI2970221T1 (sl)
TN (1) TN2015000349A1 (sl)
TW (1) TWI622396B (sl)
UA (1) UA116125C2 (sl)
WO (1) WO2014143601A1 (sl)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2615743T3 (es) * 2012-10-15 2017-06-08 Pfizer Ireland Pharmaceuticals Procedimiento de preparación de voriconazol y análogos de los mismos
WO2014110574A1 (en) 2013-01-14 2014-07-17 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors
SG10201705662WA (en) 2013-01-15 2017-08-30 Incyte Corp Thiazolecarboxamides and pyridinecarboxamide compounds useful as pim kinase inhibitors
TWI627174B (zh) 2013-03-14 2018-06-21 比利時商健生藥品公司 P2x7調控劑
NZ710034A (en) 2013-03-14 2020-06-26 Boehringer Ingelheim Int Substituted 2-aza-bicyclo[2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin c
WO2014152537A1 (en) 2013-03-14 2014-09-25 Janssen Pharmaceutica Nv P2x7 modulators
JO3773B1 (ar) 2013-03-14 2021-01-31 Janssen Pharmaceutica Nv معدلات p2x7
EP2970271B1 (en) 2013-03-14 2017-11-08 Janssen Pharmaceutica NV P2x7 modulators
PE20160532A1 (es) 2013-08-23 2016-05-21 Incyte Corp Compuesto de carboxamida de furo y tienopiridina utiles como inhibidores de cinasas pim
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
WO2016010897A1 (en) 2014-07-14 2016-01-21 Incyte Corporation Bicyclic heteroaromatic carboxamide compounds useful as pim kinase inhibitors
ES2714048T3 (es) 2014-09-12 2019-05-24 Janssen Pharmaceutica Nv Moduladores de P2X7
KR102510588B1 (ko) 2014-09-12 2023-03-17 베링거 인겔하임 인터내셔날 게엠베하 카텝신 c의 스피로사이클릭 억제제
WO2016196244A1 (en) 2015-05-29 2016-12-08 Incyte Corporation Pyridineamine compounds useful as pim kinase inhibitors
TWI734699B (zh) 2015-09-09 2021-08-01 美商英塞特公司 Pim激酶抑制劑之鹽
TW201718546A (zh) 2015-10-02 2017-06-01 英塞特公司 適用作pim激酶抑制劑之雜環化合物
EP3515903B1 (en) * 2016-09-22 2020-10-21 Cancer Research Technology Limited Preparation and uses of pyrimidinone derivatives
US10596161B2 (en) 2017-12-08 2020-03-24 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
CN108383771A (zh) * 2018-01-08 2018-08-10 华东师范大学 手性3,3-二取代异吲哚啉-1-酮衍生物及其合成方法和应用
GB201807147D0 (en) 2018-05-01 2018-06-13 Oncologica Uk Ltd Therapeutic combination
NL2021185B1 (en) 2018-06-26 2020-01-06 Stichting Het Nederlands Kanker Inst Antoni Van Leeuwenhoek Ziekenhuis Combination Therapy and Use Thereof for Treating Cancer
EP3856178A1 (en) 2018-09-28 2021-08-04 Janssen Pharmaceutica NV Monoacylglycerol lipase modulators
EP3856179A1 (en) 2018-09-28 2021-08-04 Janssen Pharmaceutica N.V. Monoacylglycerol lipase modulators
US20220220125A1 (en) * 2019-04-16 2022-07-14 Janssen Pharmaceutica Nv Fused isoindolin-1-one derivatives useful as grk2 inhibitors
US11839663B2 (en) 2019-09-30 2023-12-12 Janssen Pharmaceutica Nv Radiolabelled MGL pet ligands
JP2023518511A (ja) 2020-03-26 2023-05-01 ヤンセン ファーマシューティカ エヌ.ベー. モノアシルグリセロールリパーゼ調節因子

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0400970D0 (sv) * 2004-04-14 2004-04-14 Astrazeneca Ab Nicotinic acetylcholine receptor ligands
TW200639163A (en) * 2005-02-04 2006-11-16 Genentech Inc RAF inhibitor compounds and methods
US7576082B2 (en) * 2005-06-24 2009-08-18 Hoffman-La Roche Inc. Oxindole derivatives
WO2008060789A2 (en) * 2006-10-12 2008-05-22 Xenon Pharmaceuticals Inc. Use of spiro-oxindole compounds as therapeutic agents
BRPI0811065A2 (pt) * 2007-06-08 2014-12-02 Abbott Lab Indazóis 5-heteroaril substituídos como inibidores de quinase
US8648069B2 (en) * 2007-06-08 2014-02-11 Abbvie Inc. 5-substituted indazoles as kinase inhibitors

Also Published As

Publication number Publication date
ME02805B (me) 2018-01-20
PE20151654A1 (es) 2015-11-12
US9156824B2 (en) 2015-10-13
RS56122B1 (sr) 2017-10-31
AU2014228374B2 (en) 2016-09-01
US20140275121A1 (en) 2014-09-18
AU2014228374A1 (en) 2015-08-06
JP6064079B2 (ja) 2017-01-18
TN2015000349A1 (en) 2017-01-03
ES2639793T3 (es) 2017-10-30
MY188145A (en) 2021-11-23
CN105008351A (zh) 2015-10-28
CL2015002530A1 (es) 2016-03-28
JP2016512498A (ja) 2016-04-28
TW201521726A (zh) 2015-06-16
BR112015020466B1 (pt) 2022-07-26
PL2970221T3 (pl) 2017-11-30
PH12015502091B1 (en) 2016-01-18
WO2014143601A1 (en) 2014-09-18
EP2970221B1 (en) 2017-06-28
CY1119199T1 (el) 2018-02-14
IL240962A0 (en) 2015-11-30
UA116125C2 (uk) 2018-02-12
PT2970221T (pt) 2017-09-22
LT2970221T (lt) 2017-09-11
MX363438B (es) 2019-03-22
NZ710392A (en) 2020-05-29
KR101718645B1 (ko) 2017-03-21
EA201591509A1 (ru) 2015-12-30
DK2970221T3 (en) 2017-07-31
CR20150416A (es) 2015-09-16
BR112015020466A8 (pt) 2019-11-12
EP2970221A1 (en) 2016-01-20
EA027012B1 (ru) 2017-06-30
CN105008351B (zh) 2017-03-15
SG11201507541PA (en) 2015-10-29
HRP20171151T1 (hr) 2017-10-06
CA2900773A1 (en) 2014-09-18
CA2900773C (en) 2018-04-17
TWI622396B (zh) 2018-05-01
GT201500263A (es) 2016-03-02
JO3383B1 (ar) 2019-03-13
MX2015012583A (es) 2016-01-20
HK1212696A1 (zh) 2016-06-17
IL240962B (en) 2020-04-30
AP2015008734A0 (en) 2015-09-30
BR112015020466A2 (pt) 2017-07-18
HUE033482T2 (en) 2017-12-28
KR20150119101A (ko) 2015-10-23
PH12015502091A1 (en) 2016-01-18

Similar Documents

Publication Publication Date Title
HRP20190373T1 (hr) Inhibitori dnk-pk
HK1212696A1 (zh) 抑制劑
EP2968282A4 (en) HISTONDEMENTHYLASEINHIBITOREN
RS57306B1 (sr) Inhibitori dnk-pk
HK1219475A1 (zh) 腦啡肽酶抑制劑
HK1216531A1 (zh) 新的抑制劑
IL245442A0 (en) gsk–3 inhibitors
GB201305503D0 (en) Inhibitor
GB201320835D0 (en) HIF inhibitors